Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 3Phase 1/2 3Phase 3 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 18Active not recruiting 13Recruiting 12Terminated 3Unknown 2Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Breast Neoplasms 2Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × ribociclib × Clear all
NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

M.D. Anderson Cancer Center

Phase 2 Terminated
4 enrolled 7 charts
Breast

Breast Neoplasms

NCT02524119 2021-02-01

LEE001

University of Texas Southwestern Medical Center

Phase 2 Terminated
5 enrolled 9 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01919229 2016-01-01

MONALEESA-1

Novartis

Phase 2 Terminated
14 enrolled 7 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡